

QUESTIONS TO ASK YOUR DOCTOR



Patient portrayal

A combination of active medicines is needed to treat HIV and achieve an undetectable* HIV status in the body – the medicines can have side effects.^{1,2}

THESE ARE A FEW QUESTIONS YOU CAN ASK AT YOUR NEXT VISIT TO HELP YOU AND YOUR DOCTOR MAKE THE BEST DECISION FOR YOU.

- How many active ingredients are in my current regimen?
- Is changing medication an option for me?
- What are some other treatment options? Could they work for me?
- What short-term and long-term considerations should I have?
- Are there long-term effects of HIV treatment on my body?
- What would be the long-term benefit(s) of changing regimens?
- What should I be thinking about when considering another medication?
- Will my viral load stay suppressed if I switch medications?
- Is it easy to go back on my previous medication(s) if I have to?

TICK OFF THE QUESTIONS THAT ARE IMPORTANT TO YOU

ASK YOUR DOCTOR IF DOVATO IS RIGHT FOR YOU?

Scan the QR code to learn more and access useful resources available on WWW.DOVATO.CO.NZ



Patient portrayal

Please consult with your doctor or pharmacist before taking DOVATO. Because DOVATO does not cure HIV infection, patients on DOVATO may still develop other infections and illnesses linked to HIV infection. Side effects people may experience are headache, nausea, and diarrhoea.¹

*Undetectable means reducing the HIV in your blood to very low levels (<200 copies/mL for >6 months) with ART, which helps prevent sexual transmission of HIV.^{2,3}

Abbreviations: HIV, human immunodeficiency virus; ART, antiretroviral therapy; NZ, New Zealand

References: 1. GlaxoSmithKline NZ, DOVATO Consumer Medicine Information, 2025. Available at: <https://www.medsafe.govt.nz/consumers/cmi/d/dovato.pdf> (accessed Feb 2026). 2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV (updated Sept 2025). 3. EACS (European AIDS Clinical Society) Guidelines, version 13.0. Available at <https://eacs.sanfordguide.com/en/eacs-hiv/paediatric-hiv-treatment/art-initiation-and-initial-regimen> (accessed March 2026).

Dovato is a film coated tablet containing 50 mg of dolutegravir (as dolutegravir sodium) and 300 mg of lamivudine, which is used for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component. **Dovato is a Prescription Medicine. Dovato has risks and benefits and should be initiated by a doctor experienced in treating HIV. Dovato is a funded medicine; Special Authority criteria apply. Ask your doctor if Dovato is right for you.** Use strictly as directed. If you have concerns, or side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's consultation fees apply. For more information, you can view the Dovato Consumer Medicine Information at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed on behalf of ViiV Healthcare by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.** Date of Approval: **May 2026** | Date of Expiry: **May 2028** | TAPS-NP24717 | PM-NZ-DLL-PINF-260002

This material is intended for NZ audiences only. Any information provided on this document should be discussed with a healthcare professional and does not replace a healthcare professional's advice.